Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 4:40 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 409–432 of 1,466 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Infection Control Clear all
Completed Phase 2 Interventional Results available

A Study of EDP-938 in Non-hospitalized Adults With RSV Who Are at High Risk for Complications.

NCT05568706
View directory record Official record
Conditions
RSV Infection
Interventions
EDP-938, Placebo
Drug
Lead sponsor
Enanta Pharmaceuticals, Inc
Industry
Eligibility
18 Years and older
Enrollment
187 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
31
States / cities
Tempe, Arizona • Fresno, California • Lomita, California + 26 more
Source: ClinicalTrials.gov public record
Updated Aug 19, 2026 · Synced Oct 23, 2026, 4:40 PM EDT
Completed No phase listed Observational

Pharmacokinetics of Understudied Drugs Administered to Children Per Standard of Care

NCT01431326
View directory record Official record
Conditions
Adenovirus, Anesthesia, Anxiety, Anxiolysis, Autism, Autistic Disorder, Bacterial Meningitis, Bacterial Septicemia, Benzodiazepine, Bipolar Disorder, Bone and Joint Infections, Central Nervous System Infections, Convulsions, Cytomegalovirus Retinitis, Early-onset Schizophrenia Spectrum Disorders, Epilepsy, General Anesthesia, Gynecologic Infections, Herpes Simplex Virus, Infantile Hemangioma, Infection, Inflammation, Inflammatory Conditions, Intra-abdominal Infections, Lower Respiratory Tract Infections, Migraines, Pain, Pneumonia, Schizophrenia, Sedation, Seizures, Skeletal Muscle Spasms, Skin and Skin-structure Infections, Treatment-resistant Schizophrenia, Urinary Tract Infections, Withdrawal, Sepsis, Gram-negative Infection, Bradycardia, Cardiac Arrest, Cardiac Arrhythmia, Staphylococcal Infections, Nosocomial Pneumonia, Neuromuscular Blockade, Methicillin Resistant Staphylococcus Aureus, Endocarditis, Neutropenia, Headache, Fibrinolytic Bleeding, Pulmonary Arterial Hypertension, CMV Retinitis, Hypertension, Chronic Kidney Diseases, Hyperaldosteronism, Hypokalemia, Heart Failure, Hemophilia, Heavy Menstrual Bleeding, Insomnia
Interventions
The POPS study is collecting PK data on children prescribed the following drugs of interest per standard of care:
Drug
Lead sponsor
Daniel Benjamin
Other
Eligibility
Up to 21 Years
Enrollment
3,520 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2019
U.S. locations
43
States / cities
Anchorage, Alaska • Little Rock, Arkansas • La Jolla, California + 37 more
Source: ClinicalTrials.gov public record
Updated Sep 6, 2023 · Synced Oct 23, 2026, 4:40 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Improving Post-discharge Antimicrobial Use

NCT05471726
View directory record Official record
Conditions
Infections
Interventions
Prospective audit-and-feedback
Behavioral
Lead sponsor
Iowa City Veterans Affairs Medical Center
Federal
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
5
States / cities
Indianapolis, Indiana • Iowa City, Iowa • Baltimore, Maryland + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 8, 2024 · Synced Oct 23, 2026, 4:40 PM EDT
Completed Phase 2 Interventional Results available

t-PA Prophylaxis to Prevent Catheter-associated Thrombosis and Infection

NCT03672006
View directory record Official record
Conditions
Central Venous Catheter Thrombosis, Central Venous Catheter Associated Bloodstream Infection
Interventions
alteplase (recombinant t-PA), Heparin
Biological · Drug
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
Up to 18 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jul 13, 2021 · Synced Oct 23, 2026, 4:40 PM EDT
Recruiting Phase 3 Interventional

Phase III DAS181 Lower Tract PIV Infection in Immunocompromised Subjects (Substudy: DAS181 for COVID-19): RCT Study

NCT03808922
View directory record Official record
Conditions
Lower Respiratory Tract Infection, Parainfluenza, Immunocompromised, COVID-19
Interventions
DAS181, Placebo, DAS181 COVID-19, DAS181 OL
Drug
Lead sponsor
Ansun Biopharma, Inc.
Industry
Eligibility
Not listed
Enrollment
274 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2028
U.S. locations
23
States / cities
Duarte, California • Sacramento, California • Chicago, Illinois + 17 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2026 · Synced Oct 23, 2026, 4:40 PM EDT
Completed Phase 1Phase 2 Interventional

Nebulized Bacteriophage Therapy in Cystic Fibrosis Patients With Chronic Pseudomonas Aeruginosa Pulmonary Infection

NCT05010577
View directory record Official record
Conditions
Chronic Pseudomonas Aeruginosa Infection, Cystic Fibrosis
Interventions
BX004-A, Placebo
Drug
Lead sponsor
BiomX, Inc.
Industry
Eligibility
18 Years and older
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
18
States / cities
Birmingham, Alabama • Anchorage, Alaska • Little Rock, Arkansas + 15 more
Source: ClinicalTrials.gov public record
Updated Jul 18, 2025 · Synced Oct 23, 2026, 4:40 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Trial to Evaluate the Use of Pomegranate Concentrate (POMx) for the Prevention of Experimental Rhinovirus Infection

NCT00655031
View directory record Official record
Conditions
Common Cold
Interventions
Pomegranate Concentrate (POMx), Placebo
Dietary Supplement
Lead sponsor
POM Wonderful LLC
Industry
Eligibility
18 Years to 45 Years
Enrollment
150 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
3
States / cities
Huntsville, Alabama • Melbourne, Florida • Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Aug 18, 2008 · Synced Oct 23, 2026, 4:40 PM EDT
Completed Not applicable Interventional

Increasing HCV Linkage to Care Among People Who Inject Drugs

NCT04741750
View directory record Official record
Conditions
Hepatitis C
Interventions
Simplified HCV care within a mobile medical unit
Other
Lead sponsor
Family Health Centers of San Diego
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Feb 7, 2024 · Synced Oct 23, 2026, 4:40 PM EDT
Terminated Phase 2 Interventional

NLA101 in Adults Receiving High Dose Chemotherapy for AML

NCT03301597
View directory record Official record
Conditions
Leukemia, Myeloid, Acute
Interventions
NLA101, Standard of Care (SOC) chemotherapy
Biological · Drug
Lead sponsor
Nohla Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
146 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
25
States / cities
La Jolla, California • Los Angeles, California • Sacramento, California + 19 more
Source: ClinicalTrials.gov public record
Updated Mar 30, 2021 · Synced Oct 23, 2026, 4:40 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Magnesium Supplementation in People With XMEN Syndrome

NCT02496676
View directory record Official record
Conditions
XMEN
Interventions
Magnesium L-threonate, Placebo, Intravenous (IV) magnesium sulfate (MgSO4)
Dietary Supplement · Other · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
6 Years and older · Male only
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 2, 2022 · Synced Oct 23, 2026, 4:40 PM EDT
Completed Phase 3 Interventional

The Use of Two YUTIQ Versus Sham for Treatment of Chronic Non Infectious Intraocular Inflammation Affecting the Posterior Segment

NCT05486468
View directory record Official record
Conditions
Uveitis, Uveitis, Posterior, Uveitis, Anterior, Uveitis, Intermediate
Interventions
Yutiq 0.18 MG Drug Implant, Sham Injection
Drug · Other
Lead sponsor
Texas Retina Associates
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Plano, Texas
Source: ClinicalTrials.gov public record
Updated Oct 5, 2026 · Synced Oct 23, 2026, 4:40 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

A Study to Evaluate the Safety and Efficacy of MEDI8897 for the Prevention of Medically Attended RSV LRTI in Healthy Preterm Infants.

NCT02878330
View directory record Official record
Conditions
Respiratory Syncytial Virus Infections
Interventions
MEDI8897, Placebo
Drug
Lead sponsor
MedImmune LLC
Industry
Eligibility
Up to 365 Days
Enrollment
1,453 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
60
States / cities
Birmingham, Alabama • Anaheim, California • Downey, California + 53 more
Source: ClinicalTrials.gov public record
Updated Oct 14, 2019 · Synced Oct 23, 2026, 4:40 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Sodium Pyruvate Nasal Spray Treatment of COVID-19 Infection

NCT04824365
View directory record Official record
Conditions
COVID-19
Interventions
Sodium Pyruvate, Saline
Drug · Other
Lead sponsor
Cellular Sciences, inc.
Industry
Eligibility
18 Years to 40 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
2
States / cities
Virginia Gardens, Florida • Springfield, Missouri
Source: ClinicalTrials.gov public record
Updated Nov 2, 2022 · Synced Oct 23, 2026, 4:40 PM EDT
Completed No phase listed Observational

A Quality Initiative to Improve Glycemic Control in Diabetic and Non-Diabetic Insulin Study

NCT01916733
View directory record Official record
Conditions
Glycemic Control, Surgical Site Infections, Cardiac Complications, Length of Stay, Cost
Interventions
standard insulin protocol post-op (continuous IV insulin)
Drug
Lead sponsor
University of Vermont Medical Center
Other
Eligibility
18 Years to 99 Years
Enrollment
89 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Burlington, Vermont
Source: ClinicalTrials.gov public record
Updated Oct 25, 2016 · Synced Oct 23, 2026, 4:40 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Mobile Messaging Intervention to Present New HIV Prevention Options for Men Who Have Sex With Men (MSM)

NCT03666247
View directory record Official record
Conditions
Human Immunodeficiency Virus
Interventions
HealthMindr Application, Waitlist
Behavioral
Lead sponsor
Emory University
Other
Eligibility
18 Years and older · Male only
Enrollment
1,229 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
3
States / cities
Atlanta, Georgia • Detroit, Michigan • New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 6, 2020 · Synced Oct 23, 2026, 4:40 PM EDT
Completed Not applicable Interventional

Effect of CAUTI Prevention Alert - A Randomized Control Trial

NCT02054065
View directory record Official record
Conditions
Infection Due to Indwelling Urinary Catheter
Interventions
CAUTI Decision Support
Other
Lead sponsor
Montefiore Medical Center
Other
Eligibility
21 Years and older
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 11, 2018 · Synced Oct 23, 2026, 4:40 PM EDT
Completed Phase 2 Interventional Results available

Trial of Intravenous Azithromycin to Eradicate Ureaplasma Respiratory Tract Infection in Preterm Infants

NCT01778634
View directory record Official record
Conditions
Ureaplasma Infections
Interventions
Azithromycin, Placebo
Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
2 Hours to 72 Hours
Enrollment
121 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2020
U.S. locations
7
States / cities
Birmingham, Alabama • Newark, Delaware • Baltimore, Maryland + 2 more
Source: ClinicalTrials.gov public record
Updated Nov 30, 2020 · Synced Oct 23, 2026, 4:40 PM EDT
Terminated Phase 2 Interventional Results available

Study of ARC-520 in Participants With Hepatitis B Virus e Antigen (HBeAg) Positive Chronic Hepatitis B Virus

NCT02452528
View directory record Official record
Conditions
Chronic Hepatitis B
Interventions
ARC-520, Placebo, Entecavir, Tenofovir, diphenhydramine
Drug
Lead sponsor
Arrowhead Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
4
States / cities
San Francisco, California • Miami, Florida • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 3, 2025 · Synced Oct 23, 2026, 4:40 PM EDT
Completed No phase listed Observational Results available

Effectiveness of BNT162b2 Formulations Using State Vaccine Registry and Insurance Claims Data

NCT06199934
View directory record Official record
Conditions
SARS-CoV-2, COVID-19 Vaccines
Interventions
Vaccination
Biological
Lead sponsor
Pfizer
Industry
Eligibility
Not listed
Enrollment
19,853,610 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 10, 2025 · Synced Oct 23, 2026, 4:40 PM EDT
Completed Not applicable Interventional Results available

Precision Diagnosis of Acute Infectious Diseases; Neuroinflammatory Cohort

NCT02910037
View directory record Official record
Conditions
Encephalitis, Meningitis
Interventions
mNGS for pathogen detection
Device
Lead sponsor
University of California, San Francisco
Other
Eligibility
1 Minute to 110 Years
Enrollment
214 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
7
States / cities
Davis, California • Los Angeles, California • San Francisco, California + 3 more
Source: ClinicalTrials.gov public record
Updated May 27, 2021 · Synced Oct 23, 2026, 4:40 PM EDT
Terminated Phase 2 Interventional Results available

NasoVAX in Patients With Early Coronavirus Infectious Disease 2019 (COVID-19)

NCT04442230
View directory record Official record
Conditions
Coronavirus Infection
Interventions
NasoVAX, Placebo
Biological · Other
Lead sponsor
Altimmune, Inc.
Industry
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
7
States / cities
Miami, Florida • Morrow, Georgia • Chicago, Illinois + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 4, 2022 · Synced Oct 23, 2026, 4:40 PM EDT
Completed Phase 1 Interventional

A Study of ART24 in Subjects Recently Cured of a Clostridioides Difficile Infection (CDI)

NCT04891965
View directory record Official record
Conditions
Clostridium Difficile Infection Recurrence
Interventions
ART24, Placebo
Biological · Drug
Lead sponsor
Adiso Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
13
States / cities
Palm Springs, California • Clearwater, Florida • Doral, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Oct 17, 2022 · Synced Oct 23, 2026, 4:40 PM EDT
Not listed Phase 4 Interventional

Gentamicin Bladder Instillation Trial

NCT01884467
View directory record Official record
Conditions
Urinary Tract Infections
Interventions
Gentamicin, Placebo
Drug
Lead sponsor
Gillette Children's Specialty Healthcare
Other
Eligibility
16 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Saint Paul, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 9, 2015 · Synced Oct 23, 2026, 4:40 PM EDT
Completed Not applicable Interventional

Study to Determine if Gloving in Addition to Hand Hygiene Will Prevent Invasive Infections and Necrotizing Enterocolitis

NCT01729000
View directory record Official record
Conditions
Neonatal Infection, Neonatal Necrotizing Enterocolitis
Interventions
Gloves
Other
Lead sponsor
University of Virginia
Other
Eligibility
Up to 8 Days
Enrollment
124 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Nov 20, 2012 · Synced Oct 23, 2026, 4:40 PM EDT